These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24083721)

  • 21. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
    Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
    Pataer A; Kalhor N; Correa AM; Raso MG; Erasmus JJ; Kim ES; Behrens C; Lee JJ; Roth JA; Stewart DJ; Vaporciyan AA; Wistuba II; Swisher SG;
    J Thorac Oncol; 2012 May; 7(5):825-32. PubMed ID: 22481232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
    Li X; Shao M; Wang S; Zhao X; Chen H; Qian J; Song X; Wang J; Jin L; Wu J; Li Q; Bai C; Han B; Gao Z; Lu D
    Tumour Biol; 2014 Nov; 35(11):11159-70. PubMed ID: 25104092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
    Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
    Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer.
    Ahn HK; Jung M; Sym SJ; Shin DB; Kang SM; Kyung SY; Park JW; Jeong SH; Cho EK
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):277-82. PubMed ID: 24906423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
    Edelman MJ; Belani CP; Socinski MA; Ansari RH; Obasaju CK; Chen R; Monberg MJ; Treat J;
    J Thorac Oncol; 2010 Jan; 5(1):110-6. PubMed ID: 20035187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer.
    Greco FA; Burris HA; Hainsworth JD
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):31-4. PubMed ID: 10960943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
    Weissman CH; Reynolds CH; Neubauer MA; Pritchard S; Kobina S; Asmar L
    J Thorac Oncol; 2011 Feb; 6(2):358-64. PubMed ID: 21206386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
    Iranzo V; Sirera R; Carrato A; Cabrera A; Jantus E; Guijarro R; Sanmartín E; Blasco A; Gil M; Gómez-Aldaraví L; González-Larriba JL; Massuti B; Velasco A; Provencio M; Rossell R; Camps C
    Clin Transl Oncol; 2011 Jun; 13(6):411-8. PubMed ID: 21680302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.
    Biesma B; Wymenga ANM; Vincent A; Dalesio O; Smit HJM; Stigt JA; Smit EF; van Felius CL; van Putten JWG; Slaets JPJ; Groen HJM;
    Ann Oncol; 2011 Jul; 22(7):1520-1527. PubMed ID: 21252061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study.
    Illiano A; Barletta E; De Marino V; Battiloro C; Barzelloni M; Scognamiglio F; Rossi N; Zampa G; De Bellis M; Gridelli C
    Anticancer Res; 2000; 20(5C):3999-4003. PubMed ID: 11268491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
    Najjar F; Alammar M; Bachour M; Almalla N; Altahan M; Alali A; Al-Massarani G
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):119-25. PubMed ID: 25037116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
    Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
    Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
    Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
    Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
    Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
    Quoix E; Zalcman G; Oster JP; Westeel V; Pichon E; Lavolé A; Dauba J; Debieuvre D; Souquet PJ; Bigay-Game L; Dansin E; Poudenx M; Molinier O; Vaylet F; Moro-Sibilot D; Herman D; Bennouna J; Tredaniel J; Ducoloné A; Lebitasy MP; Baudrin L; Laporte S; Milleron B;
    Lancet; 2011 Sep; 378(9796):1079-88. PubMed ID: 21831418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.